<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02037477</url>
  </required_header>
  <id_info>
    <org_study_id>TAK-438/CPH-010</org_study_id>
    <secondary_id>U1111-1152-3926</secondary_id>
    <secondary_id>JapicCTI-142411</secondary_id>
    <secondary_id>JapicCTI-R150821</secondary_id>
    <nct_id>NCT02037477</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Acid-Inhibitory Effect of Multiple Oral Doses of Vonoprazan (TAK-438)</brief_title>
  <official_title>Phase 3 Open-Label Crossover Pharmacodynamic Study to Evaluate the Acid-inhibitory Effect of TAK-438 20 mg With Esomeprazole 20 mg or Rabeprazole Sodium 10 mg in Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the acid-inhibitory effect of multiple oral doses
      of Vonoprazan (TAK-438) and the relative effect of vonoprazan versus two controls
      (esomeprazole and rabeprazole sodium) in healthy Japanese adult male participants with the
      CYP2C19 extensive metabolizer (EM) genotype.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 3 open-label crossover study to evaluate the acid-inhibitory effect following
      7 days multiple doses of vonoprazan (20 mg per dose) and esomeprazole (20 mg per dose)
      (Cohort 1) or vonoprazan (20 mg per dose) and rabeprazole sodium (10 mg per dose) (Cohort 2)
      in healthy Japanese adult male participants (CYP2C19 genotype: EM). There will be a total of
      20 participants, 5 per group for both Cohorts 1 and 2. At least 2 participants each with the
      homo EM (*1/*1) or hetero EM (*1/*2, *1/*3) CYP2C19 genotype will be enrolled among the 5
      participants per group.

      The drug being tested in this study is called vonoprazan. This study will look at the acid
      inhibitory effect following 7 days multiple doses of vonoprazan and esomeprazole (Cohort 1)
      or vonoprazan and rabeprazole sodium (Cohort 2) in healthy Japanese adult male participants
      with the CYP2C19 EM genotype.

      The study will enroll a total of 20 participants, 5 per group for both Cohorts. At least 2
      participants each with the homo EM (*1/*1) or hetero EM (*1/*2, *1/*3) CYP2C19 genotype will
      be enrolled among the 5 participants per group.

        -  Group A, Cohort 1: vonoprazan (20 mg per dose for 7 days) followed by esomeprazole (20
           mg per dose for 7 days)

        -  Group B, Cohort 1: esomeprazole (20 mg per dose for 7 days) followed by TAK-438 (20 mg
           per dose for 7 days)

        -  Group C, Cohort 2: vonoprazan (20 mg per dose for 7 days) followed by rabeprazole sodium
           (10 mg per dose for 7 days)

        -  Group D, Cohort 2: rabeprazole sodium (10 mg per dose for 7 days) followed by vonoprazan
           (20 mg per dose for 7 days).

      All participants will be asked to take Study Medication at the same time each day throughout
      the study. This single center trial will be conducted in Japan. The overall time to
      participate in this study is 31 days.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intragastric pH Time Course Over 24 Hours</measure>
    <time_frame>At baseline (Day -2 to Day -1), administration period (Days 1 to Day 2 and Days 7 to Day 8)</time_frame>
    <description>Intragastric pH was measured continuously for 24 hours (hr) by pH monitor. pH holding time ratio (HTR) is the percentage of time a pH is maintained at a particular level. For example, pH 4 HTR is the percentage of time the pH = 4.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>31 days</time_frame>
    <description>The frequency of adverse events by type, seriousness, time to onset. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal Changes From Baseline in Vital Signs</measure>
    <time_frame>At screening, baseline (Day -3, Day -2, Day -1), administration period (Days 1, Day 2, Day 7, Day 8), and post-test (Day 28)</time_frame>
    <description>Vital signs included body temperature (oral or tympanic measurement), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Abnormal 12-lead Electrocardiogram (at Rest) Findings</measure>
    <time_frame>At Screening, baseline (Day -3), administration period (Day 8), and post-test (Day 28)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Markedly Abnormal Laboratory Values</measure>
    <time_frame>At Screening, baseline (Day -3), administration period (Day 1, Day 8), and post-test (Day 28)</time_frame>
    <description>The number of participants with markedly abnormal laboratory values for Chemistry, Hematology and Urinalysis during the study is reported.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Sequence A (Cohort 1): Vonoprazan + Esomeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vonoprazan (TAK-438) 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then esomeprazole 20 mg, orally, once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence B (Cohort 1): Esomeprazole + Vonoprazan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Esomeprazole 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vonoprazan 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then Rabeprazole sodium 10 mg, orally, once daily for 7 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rabeprazole sodium 10 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days; then vonoprazan 20 mg, orally, once daily for 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vonoprazan</intervention_name>
    <description>Vonoprazan tablets</description>
    <arm_group_label>Sequence A (Cohort 1): Vonoprazan + Esomeprazole</arm_group_label>
    <arm_group_label>Sequence B (Cohort 1): Esomeprazole + Vonoprazan</arm_group_label>
    <arm_group_label>Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium</arm_group_label>
    <arm_group_label>Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan</arm_group_label>
    <other_name>TAK-438</other_name>
    <other_name>TakecabÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esomeprazole</intervention_name>
    <description>Esomeprazole capsules</description>
    <arm_group_label>Sequence A (Cohort 1): Vonoprazan + Esomeprazole</arm_group_label>
    <arm_group_label>Sequence B (Cohort 1): Esomeprazole + Vonoprazan</arm_group_label>
    <other_name>Nexium (esomeprazole)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rabeprazole sodium</intervention_name>
    <description>Rabeprazole sodium tablets</description>
    <arm_group_label>Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium</arm_group_label>
    <arm_group_label>Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan</arm_group_label>
    <other_name>Pariet (rabeprazole)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is a healthy Japanese adult male volunteer.

          2. Is aged 20 to 45 years, inclusive, at the time of informed consent.

          3. Has been confirmed at CYP2C19 genotyping as an Extensive Metabolizer [EM
             (*1/*1,*1/*2,*1/*3)].

          4. Capable of understanding and complying with the protocol requirements.

          5. The participant signs and dates a written informed consent form prior to the
             initiation of any study procedures.

          6. Weighs 50 kg or more and has body mass index (BMI) of 18.5 or more and less than 25.0
             kg/m^2 at Screening or admission (Day -3).

          7. H. pylori-negative at Screening.

        Exclusion Criteria:

          1. Has undergone resection of the upper gastrointestinal tract or vagotomy.

          2. Was determined to have hypoacidity or anacidity.

          3. Has a present or past history of acid-related disease (reflux esophagitis, gastric
             ulcer, duodenal ulcer, non-erosive gastroesophageal reflux, Barrett's esophagus,
             Zollinger-Ellison syndrome, etc.).

          4. Has undergone eradication of H. pylori within 6 months prior to the start of the study
             drug administration.

          5. Has uncontrolled, clinically significant neurologic, cardiovascular, pulmonary,
             hepatic, renal, metabolic, gastrointestinal, or endocrine disease or other
             abnormalities which may impact the ability of the subject to participate or
             potentially confound the study results.

          6. Has a known hypersensitivities or allergies to drugs or food.

          7. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol
             abuse within 5 years prior to the start of the study drug administration.

          8. Has poor peripheral venous access.

          9. Had 200 mL or more of whole blood drawn within 4 weeks (28 days) prior to the start of
             the study drug administration or 400 mL or more of whole blood drawn within 12 weeks
             (84 days) prior to the start of the study drug administration.

         10. Had a total volume of 800 mL or more of whole blood drawn within 52 weeks (364 days)
             prior to the start of the study drug administration.

         11. Has undergone blood component draw within 2 weeks (14 days) prior to the start of the
             study drug administration.

         12. Requires treatment with any of the excluded medications specified in the study or
             requires nutrition with any vitamin supplements or foods prohibited in the study.

         13. Has received study medication within 16 weeks (112 days) prior to the start of the
             study drug administration.

         14. Has received vonoprazan (TAK-438) in the past.

         15. Has a history of cancer.

         16. Has a positive test result for hepatitis B surface antigen (HBsAg), hepatitis C virus
             (HCV) antibody, human immunodeficiency virus (HIV) antibody/antigen or serological
             reaction for syphilis at Screening.

         17. Has a Screening or admission (Day -3) abnormal clinically significant
             electrocardiogram (ECG).

         18. Has abnormal Screening or admission (Day -3) laboratory values that suggest a
             clinically significant underlying disease or subject with the following lab
             abnormalities: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt;
             twice the upper limit of the normal range.

         19. Is an immediate family member, study site employee, or in a dependent relationship
             with a study site employee who is involved in the conduct of this study (e.g., spouse,
             parent, child, sibling) or may consent under duress.

         20. Participant who, in the opinion of the investigator or sub-investigator, is unlikely
             to comply with the protocol or is unsuitable for any other reasons.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>General Manager</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <results_first_submitted>March 27, 2015</results_first_submitted>
  <results_first_submitted_qc>August 22, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 17, 2016</results_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Rabeprazole</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants took part in the study at 1 investigative site in Japan from 3 February 2014 to 27 March 2014.</recruitment_details>
      <pre_assignment_details>A total of 56 participants signed the informed consent form. 20 participants were enrolled and received the study drug. The primary reason for ineligibility to receive the study drug was âdid not meet entrance criteriaâ for 16 subjects. Nineteen subjects completed the study, while 1 subject withdrew due to a âpretreatment event/AE.â</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sequence A (Cohort 1): Vonoprazan + Esomeprazole</title>
          <description>Vonoprazan (TAK-438) 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days and then esomeprazole 20 mg, orally, once daily for 7 days.</description>
        </group>
        <group group_id="P2">
          <title>Sequence B (Cohort 1): Esomeprazole + Vonoprazan</title>
          <description>Esomeprazole 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days and then vonoprazan 20 mg, orally, once daily for 7 days.</description>
        </group>
        <group group_id="P3">
          <title>Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium</title>
          <description>Vonoprazan 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days and then rabeprazole sodium 10 mg, orally, once daily for 7 days.</description>
        </group>
        <group group_id="P4">
          <title>Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan</title>
          <description>Rabeprazole sodium 10 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days and then vonoprazan 20 mg, orally, once daily for 7 days.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Pre-treatment Event/Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sequence A (Cohort 1): Vonoprazan + Esomeprazole</title>
          <description>Vonoprazan (TAK-438) 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days and then esomeprazole 20 mg, orally, once daily for 7 days.</description>
        </group>
        <group group_id="B2">
          <title>Sequence B (Cohort 1): Esomeprazole + Vonoprazan</title>
          <description>Esomeprazole 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days and then vonoprazan 20 mg, orally, once daily for 7 days.</description>
        </group>
        <group group_id="B3">
          <title>Sequence C (Cohort 2): Vonoprazan + Rabeprazole Sodium</title>
          <description>Vonoprazan 20 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days and then rabeprazole sodium 10 mg, orally, once daily for 7 days.</description>
        </group>
        <group group_id="B4">
          <title>Sequence D (Cohort 2): Rabeprazole Sodium + Vonoprazan</title>
          <description>Rabeprazole sodium 10 mg, orally, once daily for 7 days, followed by a washout period of at least 7 days and then vonoprazan 20 mg, orally, once daily for 7 days.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="5"/>
            <count group_id="B4" value="5"/>
            <count group_id="B5" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.0" spread="6.93"/>
                    <measurement group_id="B2" value="23.8" spread="5.17"/>
                    <measurement group_id="B3" value="22.2" spread="2.95"/>
                    <measurement group_id="B4" value="25.2" spread="2.95"/>
                    <measurement group_id="B5" value="25.2" spread="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.0" spread="7.75"/>
                    <measurement group_id="B2" value="173.0" spread="6.52"/>
                    <measurement group_id="B3" value="172.8" spread="6.76"/>
                    <measurement group_id="B4" value="169.4" spread="4.88"/>
                    <measurement group_id="B5" value="171.8" spread="6.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.10" spread="8.930"/>
                    <measurement group_id="B2" value="64.10" spread="9.813"/>
                    <measurement group_id="B3" value="62.68" spread="5.008"/>
                    <measurement group_id="B4" value="58.34" spread="5.227"/>
                    <measurement group_id="B5" value="62.31" spread="7.245"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.56" spread="1.674"/>
                    <measurement group_id="B2" value="21.32" spread="1.844"/>
                    <measurement group_id="B3" value="20.96" spread="0.808"/>
                    <measurement group_id="B4" value="20.34" spread="1.222"/>
                    <measurement group_id="B5" value="21.05" spread="1.387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CPY2C19 Genotype Test (N)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Homo Extensive Metabolizer (EM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hetero EM</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poor Metabolizer (PM)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Intragastric pH Time Course Over 24 Hours</title>
        <description>Intragastric pH was measured continuously for 24 hours (hr) by pH monitor. pH holding time ratio (HTR) is the percentage of time a pH is maintained at a particular level. For example, pH 4 HTR is the percentage of time the pH = 4.</description>
        <time_frame>At baseline (Day -2 to Day -1), administration period (Days 1 to Day 2 and Days 7 to Day 8)</time_frame>
        <population>Pharmacodynamic (PD) Analysis Set - Participants receiving study medication who completed protocol procedures without serious violation of the protocol were eligible for PD analysis. All 10 subjects from Cohort 1 were included. Three subjects in Cohort 2 were excluded from the PD analysis set, which therefore consisted of 7 subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Vonoprazan 20 mg</title>
            <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Esomeprazole 20 mg</title>
            <description>Esomeprazole 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - Vonoprazan 20 mg</title>
            <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - Rabeprazole Sodium 10 mg</title>
            <description>Rabeprazole sodium 10 mg, orally, once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Intragastric pH Time Course Over 24 Hours</title>
          <description>Intragastric pH was measured continuously for 24 hours (hr) by pH monitor. pH holding time ratio (HTR) is the percentage of time a pH is maintained at a particular level. For example, pH 4 HTR is the percentage of time the pH = 4.</description>
          <population>Pharmacodynamic (PD) Analysis Set - Participants receiving study medication who completed protocol procedures without serious violation of the protocol were eligible for PD analysis. All 10 subjects from Cohort 1 were included. Three subjects in Cohort 2 were excluded from the PD analysis set, which therefore consisted of 7 subjects.</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="7"/>
                <count group_id="O4" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>0-24 hr pH 4 HTR (%)-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.63" spread="7.391"/>
                    <measurement group_id="O2" value="10.63" spread="7.391"/>
                    <measurement group_id="O3" value="8.90" spread="6.472"/>
                    <measurement group_id="O4" value="8.90" spread="6.472"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-24 hr pH 4 HTR (%)-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.37" spread="17.030"/>
                    <measurement group_id="O2" value="23.92" spread="16.896"/>
                    <measurement group_id="O3" value="84.16" spread="12.383"/>
                    <measurement group_id="O4" value="26.29" spread="13.381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-24 hr pH 4 HTR (%)-Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.82" spread="14.748"/>
                    <measurement group_id="O2" value="61.21" spread="17.140"/>
                    <measurement group_id="O3" value="93.79" spread="7.310"/>
                    <measurement group_id="O4" value="65.09" spread="14.159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-12 hr pH 4 HTR (%)-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.98" spread="11.139"/>
                    <measurement group_id="O2" value="12.98" spread="11.139"/>
                    <measurement group_id="O3" value="8.01" spread="5.730"/>
                    <measurement group_id="O4" value="8.01" spread="5.730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-12 hr pH 4 HTR (%)-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.83" spread="9.681"/>
                    <measurement group_id="O2" value="34.89" spread="24.645"/>
                    <measurement group_id="O3" value="84.03" spread="7.810"/>
                    <measurement group_id="O4" value="37.26" spread="20.384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>0-12 hr pH 4 HTR (%)-Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.45" spread="4.402"/>
                    <measurement group_id="O2" value="77.62" spread="17.302"/>
                    <measurement group_id="O3" value="98.83" spread="2.968"/>
                    <measurement group_id="O4" value="76.06" spread="9.591"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-24 hr pH 4 HTR (%)-Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.18" spread="13.735"/>
                    <measurement group_id="O2" value="8.18" spread="13.735"/>
                    <measurement group_id="O3" value="9.77" spread="14.096"/>
                    <measurement group_id="O4" value="9.77" spread="14.096"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-24 hr pH 4 HTR (%)-Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.86" spread="28.345"/>
                    <measurement group_id="O2" value="12.94" spread="10.876"/>
                    <measurement group_id="O3" value="84.34" spread="20.254"/>
                    <measurement group_id="O4" value="15.34" spread="13.317"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-24 hr pH 4 HTR (%)-Day 7</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.21" spread="26.398"/>
                    <measurement group_id="O2" value="44.81" spread="17.338"/>
                    <measurement group_id="O3" value="88.77" spread="14.369"/>
                    <measurement group_id="O4" value="54.13" spread="25.275"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency of Adverse Events</title>
        <description>The frequency of adverse events by type, seriousness, time to onset. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.</description>
        <time_frame>31 days</time_frame>
        <population>Safety analysis set - All participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Vonoprazan 20 mg</title>
            <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Esomeprazole 20 mg</title>
            <description>Esomeprazole 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - Vonoprazan 20 mg</title>
            <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - Rabeprazole Sodium 10 mg</title>
            <description>Rabeprazole sodium 10 mg, orally, once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Frequency of Adverse Events</title>
          <description>The frequency of adverse events by type, seriousness, time to onset. Adverse events are defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a medicinal product reported from first dose of study drug to the last dose of study drug.</description>
          <population>Safety analysis set - All participants who received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Treatment Emergent Adverse Events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Related</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leading to Study Drug Discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal Changes From Baseline in Vital Signs</title>
        <description>Vital signs included body temperature (oral or tympanic measurement), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).</description>
        <time_frame>At screening, baseline (Day -3, Day -2, Day -1), administration period (Days 1, Day 2, Day 7, Day 8), and post-test (Day 28)</time_frame>
        <population>Safety analysis set - All participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Vonoprazan 20 mg</title>
            <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Esomeprazole 20 mg</title>
            <description>Esomeprazole 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - Vonoprazan 20 mg</title>
            <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - Rabeprazole Sodium 10 mg</title>
            <description>Rabeprazole sodium 10 mg, orally, once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal Changes From Baseline in Vital Signs</title>
          <description>Vital signs included body temperature (oral or tympanic measurement), sitting blood pressure (after the participant has rested for at least 5 minutes), and pulse (bpm).</description>
          <population>Safety analysis set - All participants who received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Abnormal 12-lead Electrocardiogram (at Rest) Findings</title>
        <time_frame>At Screening, baseline (Day -3), administration period (Day 8), and post-test (Day 28)</time_frame>
        <population>Safety analysis set - All participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Vonoprazan 20 mg</title>
            <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Esomeprazole 20 mg</title>
            <description>Esomeprazole 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - Vonoprazan 20 mg</title>
            <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - Rabeprazole Sodium 10 mg</title>
            <description>Rabeprazole sodium 10 mg, orally, once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Abnormal 12-lead Electrocardiogram (at Rest) Findings</title>
          <population>Safety analysis set - All participants who received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Markedly Abnormal Laboratory Values</title>
        <description>The number of participants with markedly abnormal laboratory values for Chemistry, Hematology and Urinalysis during the study is reported.</description>
        <time_frame>At Screening, baseline (Day -3), administration period (Day 1, Day 8), and post-test (Day 28)</time_frame>
        <population>Safety analysis set - All participants who received at least 1 dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1 - Vonoprazan 20 mg</title>
            <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1 - Esomeprazole 20 mg</title>
            <description>Esomeprazole 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 2 - Vonoprazan 20 mg</title>
            <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 2 - Rabeprazole Sodium 10 mg</title>
            <description>Rabeprazole sodium 10 mg, orally, once daily for 7 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Markedly Abnormal Laboratory Values</title>
          <description>The number of participants with markedly abnormal laboratory values for Chemistry, Hematology and Urinalysis during the study is reported.</description>
          <population>Safety analysis set - All participants who received at least 1 dose of study drug.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>31 Days</time_frame>
      <desc>At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1 - Vonoprazan 20 mg</title>
          <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1 - Esomeprazole 20 mg</title>
          <description>Esomeprazole 20 mg, orally, once daily for 7 days.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 2 - Vonoprazan 20 mg</title>
          <description>Vonoprazan 20 mg, orally, once daily for 7 days.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 2 - Rabeprazole Sodium 10 mg</title>
          <description>Rabeprazole sodium 10 mg, orally, once daily for 7 days.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 16.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The first study related publication will be a multi-center publication submitted within 24 months after conclusion or termination of a study at all sites. After such multi-site publication, all proposed site publications and presentations will be submitted to sponsor for review 60 days in advance of publication. Site will remove Sponsor confidential information unrelated to study results. Sponsor can delay a proposed publication for another 60 days to preserve intellectual property.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director, Clinical Science</name_or_title>
      <organization>Takeda</organization>
      <phone>+1-877-825-3327</phone>
      <email>trialdisclosures@takeda.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

